Mash et al. 2018: Oral Ibogaine Detoxification Open-Label Series (N=191) — Frontiers in Pharmacology

Definition box

Definition: Mash, Duque, Page & Allen-Ferdinand (2018) in *Frontiers in Pharmacology* (doi: 10.3389/fphar.2018.00529) is an open-label case series of N=191 human volunteers seeking inpatient medical detoxification from opioids or cocaine with oral ibogaine HCl. Authors reported diminished opioid withdrawal symptoms, reduced heroin and cocaine craving on multi-dimensional questionnaires, mood improvements at discharge, and reviewed one-month follow-up craving data where available, alongside pharmacokinetic blood assays and adverse-event observation in a medically monitored inpatient setting. This is not a randomized controlled trial, not FDA approval evidence, and not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). The paper itself supports product-development interest in single oral dose ibogaine for opioid withdrawal—not IV psychoactive branding. Cardiac QTc risk remains central across the broader literature. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (58 words)

Mash and colleagues’ 2018 Frontiers open-label series of 191 people found oral ibogaine associated with reduced opioid withdrawal and heroin/cocaine craving under inpatient monitoring—not an RCT and not evidence for psychoactive IV ibogaine infusion. Authors framed oral single-dose product development. Cardiac QTc risk still matters. Ibogaine is not FDA-approved.

Why this paper-spoke exists

Mash 2018 is one of the largest modern oral clinical case series in the ibogaine addiction literature. Marketing sometimes inflates N=191 into “clinically proven IV detox” or guaranteed abstinence rates. This spoke keeps design, route, and evidence gap labeled.

Addiction hub: /ibogaine-for-addiction · /blog/ibogaine-for-cocaine-stimulants · /blog/ibogaine-for-fentanyl · Oral vs IV: /blog/ibogaine-oral-vs-iv · Entity: /what-is-ibogaine-infusion.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Mash D.C., Duque L., Page B., Allen-Ferdinand K. *Front Pharmacol*. 2018;9:529. doi 10.3389/fphar.2018.00529 | | Design | Open-label case series / clinical observations with medical monitoring | | N | 191 volunteers seeking detoxification from opioids or cocaine | | Setting | Inpatient treatment with medical monitoring (as described by authors) | | Psychoactive route | Oral ibogaine HCl (authors discuss effective oral dose ranges for blocking opioid withdrawal; commonly summarized around 8–12 mg/kg in secondary clinical discussions of this series) | | Measures | Opioid withdrawal symptoms; multi-dimensional craving questionnaires (heroin & cocaine); standardized health/mood questionnaires; PK blood assays; AE review | | Follow-up | Program discharge assessments; one-month craving follow-up where available | | What it is not | Placebo-controlled RCT; IV-psychoactive ibogaine proof; FDA approval package; population cure-rate certificate |

Open the primary paper (PMC5996271) for exact instruments, PK tables, AE definitions, and limitation language.

Methods (plain language)

Researchers reviewed clinical results from an open-label inpatient series of adults seeking to detoxify from opioids or cocaine. Participants received oral ibogaine under medical monitoring. Whole blood was assayed for pharmacokinetic measures of ibogaine metabolism and clearance. Clinical safety and adverse events were studied in male and female subjects. Craving and mood instruments were administered around detoxification and at discharge; one-month data were reviewed when available to see whether craving reductions persisted outside the inpatient setting.

Plain-language implications:

1. Open-label — expectancy and non-blinded ratings can inflate apparent benefit.
2. No randomized control arm — cannot isolate drug effect from setting, counseling, or time.
3. Large N relative to many ibogaine papers — still not an efficacy RCT.
4. Mixed opioid/cocaine population — signals may differ by primary substance.
5. One-month follow-up incomplete for all — durability claims must stay modest.
6. Authors’ own product-development framing targets oral single-dose development—not psychoactive IV proof.

Key findings (no hype)

As reported by the authors:

• Oral ibogaine in a monitored dose range was associated with diminished opioid withdrawal symptoms.
• Multi-dimensional craving questionnaires showed reductions in heroin and cocaine craving during inpatient detoxification.
• Standardized health and mood questionnaires improved from before to after treatment and at program discharge (as reported).
• One-month follow-up (where available) was reviewed for persistence of craving effects outside the controlled inpatient environment.
• Authors reported no significant adverse events / no significant toxicity within the dose range they judged effective for blocking opioid withdrawal in this series—a claim that must be read as series-specific observation, not a population cardiac-safety certificate (broader literature documents QTc prolongation and fatalities).
• Pharmacokinetic work characterized metabolism and clearance relevant to oral dosing.

Honest reading: a large open-label oral series is scientifically useful for hypothesis generation and protocol history. It is not a substitute for RCTs, not a license to advertise cure percentages, and not evidence that psychoactive IV ibogaine is validated.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Open-label / no RCT | Expectancy, setting effects, regression to the mean | | Incomplete long-term follow-up | Discharge/1-month signals ≠ year-long abstinence rates | | Self-selected inpatient sample | Motivated detox seekers ≠ all SUD patients | | Substance heterogeneity | Opioid vs cocaine trajectories differ | | AE framing vs global cardiac literature | “No significant AEs in this dose range” ≠ zero QTc risk worldwide | | Product-development bias risk | Authors explicitly support oral product development | | Route | Oral — does not validate psychoactive IV |

Compare smaller NZ observational work with an enrolled death: /blog/noller-2018-ibogaine-new-zealand. Parallel OUD observational outcomes: /blog/brown-alper-2018-ibogaine-oud. QTc safety open-label: /blog/knuijver-2021-ibogaine-qtc-safety.

Route honesty: oral ≠ psychoactive IV

Mash 2018 administered oral ibogaine HCl and explicitly discusses single oral dose product development for opioid withdrawal. That is not this site’s entity: IV ibogaine infusion as psychoactive intravenous delivery under physician supervision.

Support IVs (fluids, magnesium, antiemetics) are not psychoactive IV ibogaine (/blog/electrolytes-support-iv-vs-psychoactive-iv). Clinics saying “we run the Mash Frontiers IV protocol” should be asked: Is ibogaine intravenous, or only support meds?

Cardiac / YMYL context

Even when a monitored series reports limited acute toxicity in its dose window, the wider evidence base links ibogaine to QTc prolongation and, in some contexts, fatal arrhythmias. Knuijver et al. (*Addiction* 2021) found mean QTc prolongation ≈ +95 ms after oral 10 mg/kg, with 50% exceeding 500 ms—no TdP in that n=14 sample, which does not prove rare-event safety.

Systematic reviews (Köck 2022; Mosca 2023) flag cardiotoxicity and mortality alongside withdrawal/craving signals. Screening and continuous monitoring remain mandatory (/safety-and-screening, /blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-mortality-cardiac-risk).

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “N=191 proves IV ibogaine detox” | False — oral open-label series | | “Clinically proven cure for opioids and cocaine” | False — not an RCT; no cure claims appropriate | | “Safe because authors reported no significant AEs in-range” | Incomplete — series observation ≠ global cardiac clearance | | “FDA-cleared detox product” | False — Schedule I; not FDA-approved | | Cite as adjacent large oral series with labels? | Yes — if design/route/N labeled |

U.S. access remains Schedule I / not FDA (/blog/is-ibogaine-legal-us, /blog/ibogaine-mexico-medical-vs-tourism).

Soft CTA

If Mash 2018’s craving/withdrawal signals prompted interest in physician-supervised IV ibogaine infusion, begin with cardiac and evidence-gap literacy: /safety-and-screening. Then request a confidential screening consult via /apply—not after inflated “191-patient proven IV” marketing.

FAQ

What did Mash et al. 2018 study? An open-label inpatient case series of 191 people seeking oral ibogaine detoxification from opioids or cocaine, with craving, withdrawal, mood, PK, and AE observations.

Was the route oral or IV? **Oral** ibogaine HCl. Authors discuss single oral dose product development—not psychoactive IV proof.

Did craving and withdrawal improve? Authors reported reduced opioid withdrawal and diminished heroin/cocaine craving under monitoring, with mood improvements at discharge; one-month data were reviewed where available.

Was this a randomized controlled trial? No. Open-label case series without a randomized placebo control.

Does N=191 make it definitive efficacy proof? No. Large relative N helps observation but does not create RCT-level causal proof.

Does this prove IV ibogaine infusion works? No. Route was oral; design was open-label.

Are cardiac risks irrelevant because AEs were limited in-series? No. Broader QTc/fatality literature still applies (/safety-and-screening).

Is ibogaine FDA-approved? No. Schedule I in the U.S.; not FDA-approved.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Mash 2018 is oral open-label detox literature—not psychoactive IV ibogaine proof.

Sources (selected)

1. Mash D.C., Duque L., Page B., Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529. PMCID: PMC5996271.
2. Brown T.K., Alper K. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802.
3. Noller G.E. et al. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1310218.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
6. Mosca A. et al. *Curr Neuropharmacol*. 2023. doi: 10.2174/1570159X21666221017085612.
7. 21 CFR 1308.11 — ibogaine Schedule I (United States).